Ritalin, Methylphenidate Newswire (Page 6)

Ritalin, Methylphenidate Newswire (Page 6)

Comprehensive Real-Time News Feed for Ritalin, Methylphenidate (generic). (Page 6)

Results 101 - 120 of 4,421 in Ritalin, Methylphenidate (generic)

  1. Cape Breton police charge couple with trafficking RitalinRead the original story w/Photo

    Sep 21, 2017 | GlobalNews

    Cape Breton Regional Police have charged a man and woman, both from New Waterford, N.S. with trafficking a drug used to treat attention deficit disorder . Police say they executed a search warrant at a home on Miner Avenue Wednesday evening and seized a large quantity of Ritalin.

    Comment?

  2. Sleep!.... Anyone seen mine?Read the original story

    Sep 20, 2017 | Sequoyah County Times

    Anytime anyone loses car keys or glasses or cell phone, everyone goes on the hunt, until the loser yells, "Found it. It was in the last place I looked."

    Comment?

  3. Wyanet man sentenced to 3 years for drug feloniesRead the original story w/Photo

    Sep 19, 2017 | Bureau County Republican

    Taylor A. Steele, 20, of Wyanet was sentenced by Circuit Judge Marc Bernabei on Sept. 11 to three years in the Illinois Department of Corrections after pleading guilty to the Class 4 felony of unlawful possession of a controlled substance and the Class 2 felony of unlawful delivery of a controlled substance .

    Comment?

  4. Neos Therapeutics (NEOS) versus The Competition Head to Head AnalysisRead the original story w/Photo

    Sep 19, 2017 | AmericanBankingNews.com

    Neos Therapeutics is one of 112 public companies in the "Pharmaceuticals" industry, but how does it contrast to its competitors? We will compare Neos Therapeutics to similar businesses based on the strength of its dividends, analyst recommendations, risk, profitability, earnings, institutional ownership and valuation. Neos Therapeutics has a beta of -0.9, suggesting that its share price is 190% less volatile than the S&P 500.

    Comment?

  5. Aceto Corporation (ACET) vs. Neos Therapeutics (NEOS) Financial ReviewRead the original story w/Photo

    Sep 19, 2017 | IntersportsWire

    Aceto Corporation and Neos Therapeutics are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings. Aceto Corporation has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500.

    Comment?

  6. Dr. Art Mollen: ADHD in adults is more common than you may thinkRead the original story w/Photo

    Sep 19, 2017 | The Arizona Republic

    Dr. Art Mollen: ADHD in adults is more common than you may think Fitness: Many adults who struggled in school and were considered underachievers may have had undiagnosed ADHD Check out this story on azcentral.com: http://azc.cc/2xebyWy If you think that you may suffer from ADHD, attention deficit hyperactivity disorder, you should be tested. However there are several conditions that can mimic ADHD, such as anxiety, bipolar depression and substance abuse.

    Comment?

  7. Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER...Read the original story w/Photo

    Sep 15, 2017 | Drugs.com

    Neos Therapeutics, Inc. , a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release products using its proprietary modified-release drug delivery technologies, today announced that the U.S. Food and Drug Administration has approved Adzenys ERa Extended-Release Oral Suspension. Neos Therapeutics is the only company to offer both branded amphetamine and methylphenidate products in extended-release dosage forms.

    Comment?

  8. Scientists genetically engineer mice that display behavioral hallmarks of human bipolar disorderRead the original story w/Photo

    Sep 18, 2017 | Medical News

    Johns Hopkins researchers report they have genetically engineered mice that display many of the behavioral hallmarks of human bipolar disorder, and that the abnormal behaviors the rodents show can be reversed using well-established drug treatments for bipolar disorder, such as lithium. Specifically, the mice lacked the protein ankyrin-G, in particular neurons in the brain, a defect that appears to make the animals both hyperactive and less fearful, a behavioral profile suggestive of a mania-like state for a mouse.

    Comment?

  9. Genetically Altered Mice Bear Some Hallmarks of Human Bipolar BehaviorRead the original story w/Photo

    Sep 18, 2017 | Health News Digest

    Johns Hopkins researchers report they have genetically engineered mice that display many of the behavioral hallmarks of human bipolar disorder, and that the abnormal behaviors the rodents show can be reversed using well-established drug treatments for bipolar disorder, such as lithium. Specifically, the mice lacked the protein ankyrin-G, in particular neurons in the brain, a defect that appears to make the animals both hyperactive and less fearful, a behavioral profile suggestive of a mania-like state for a mouse.

    Comment?

  10. "Dad, I Think I Have ADHD"Read the original story w/Photo

    Sep 17, 2017 | Psychology Today

    Your son, Marcus, a college freshman, calls you at the end of September; he is struggling in his courses. In high school, he was involved in several sports and seemed to do well in his classes without much studying. 1 comment

  11. Financial Comparison: Neos Therapeutics (NEOS) vs. Its CompetitorsRead the original story w/Photo

    Sep 17, 2017 | AmericanBankingNews.com

    Neos Therapeutics is one of 112 public companies in the "Pharmaceuticals" industry, but how does it compare to its competitors? We will compare Neos Therapeutics to related companies based on the strength of its dividends, profitability, risk, institutional ownership, analyst recommendations, earnings and valuation. This is a breakdown of recent recommendations and price targets for Neos Therapeutics and its competitors, as provided by MarketBeat.

    Comment?

  12. Neos Therapeutics sells off despite latest FDA approvalRead the original story w/Photo

    Sep 15, 2017 | Seeking Alpha

    Neos Therapeutics has gotten FDA approval for its Adzenys ER treatment for Attention Deficit Hyperactivity Disorder, but shares have fallen 5.4% in the postmarket session since the after-hours announcement. It will be Neos' third extended-release product for ADHD.

    Comment?

  13. Garth Brooks shocks pregnant couple with mid-concertaRead the original story w/Photo

    Sep 15, 2017 | KBMT

    They're expecting their first child in December and enjoying the simple things before they become a family of three. "We had a random joking moment," Wes says, "where we said, 'How cool would it be if we could get Garth to reveal the gender at the concert,' never thinking it would possibly happen."

    Comment?

  14. Shire Debuts MYDAYIS and New Research at the 30th Annual Psych CongressRead the original story

    Sep 15, 2017 | GlobeNewswire

    September 15, 2017 - Shire plc will share new Attention Deficit Hyperactivity Disorder research at the upcoming Psych Congress in New Orleans, Louisiana from September 16-19, 2017. Research will include findings about MYDAYISA , which was recently approved by the U.S. Food and Drug Administration as a once-daily treatment comprised of three different types of drug-releasing beads for patients 13 years and older with ADHD.

    Comment?

  15. Adult ADHD: Symptoms, diagnosis, and treatmentRead the original story

    Jul 17, 2017 | Medical News Today

    Attention deficit hyperactivity disorder is a medical condition that makes it difficult to pay attention, remain organized, and listen. Living with the condition can affect relationships, educational pursuits, and careers.

    Comment?

  16. ADHD medication tied to lower risk for alcohol, drug abuse in teens and adultsRead the original story w/Photo

    Jul 14, 2017 | Medical News Today

    The use of medication to treat attention deficient hyperactivity disorder is linked to significantly lower risk for substance use problems in adolescents and adults with ADHD , according to a study led by researchers at Indiana University. The risk of substance use problems during periods of medication use was 35 percent lower in men and 31 percent lower in women in the study.

    Comment?

  17. Study questions benefits of long-term use of ADHD medicationsRead the original story w/Photo

    Mar 15, 2017 | Medical News Today

    In a study that followed more than 500 children with attention-deficit/hyperactivity disorder into adulthood, extended use of stimulant medication was linked with suppressed adult height but not with reduced symptoms of ADHD. The findings suggest that short-term treatment of ADHD with stimulant medication is well justified by benefits that outweigh costs, but long-term treatment may be associated with growth-related costs that may not be balanced by symptom-related benefits.

    Comment?

  18. ADHD: Large imaging study confirms differences in several brain regionsRead the original story w/Photo

    Feb 16, 2017 | Medical News Today

    The largest imaging study of its kind finds that people diagnosed with ADHD have altered brains. It identifies size differences in several brain regions and the brain overall, with the greatest differences seen in children rather than adults.

    Comment?

  19. Can Marijuana Help Treat ADHD?Read the original story w/Photo

    Jan 13, 2017 | Medical News Today

    Attention deficit hyperactivity disorder is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity. Treatments vary, but some people use marijuana to help relieve symptoms.

    Comment?

  20. Illicit drug use may affect sexual function in menRead the original story w/Photo

    Jul 7, 2015 | Medical News Today

    In a study of 1159 males who illicitly used amphetamines, half of participants said drug use had no impact on their sexual functions, while the other half reported impacts such as reduced erectile rigidity and sexual satisfaction, enhanced orgasmic intensity, and delayed ejaculation. "Compared with 211 matched controls, amphetamine users were twice as likely to experience erectile dysfunction ," said Dr. Bang-Ping Jiann, senior author of The Journal of Sexual Medicine study.

    Comment?